TherapeuticsMD (TXMD) Accumulated Expenses (2011 - 2026)

TherapeuticsMD's Accumulated Expenses history runs 16 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• Quarterly Accumulated Expenses rose 1627.91% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (up 1627.91% YoY) and the FY2025 annual result came in at $1.7 million, down 18.15% from the prior year.
• Accumulated Expenses was $2.2 million for Q1 2026 at TherapeuticsMD, up from $1.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $18.8 million in Q4 2022 and bottomed at $129000.0 in Q1 2025.
• A 5-year average of $3.4 million and a median of $2.1 million in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses plunged 95.96% — and 2026, when it surged 1627.91%.
• TherapeuticsMD's Accumulated Expenses stood at $18.8 million in 2022, then plunged by 95.96% to $762000.0 in 2023, then surged by 179.13% to $2.1 million in 2024, then fell by 18.15% to $1.7 million in 2025, then grew by 28.03% to $2.2 million in 2026.
• Business Quant data shows TXMD's Accumulated Expenses at $2.2 million in Q1 2026, $1.7 million in Q4 2025, and $2.0 million in Q3 2025.